Diffuse large b-cell lymphoma version 1.2016: Clinical practice guidelines in oncology

Andrew D. Zelenetz; Leo I. Gordon; William G. Wierda; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; Nancy Bartlett; John C. Byrd; Luis E. Fayad; Richard I. Fisher; Martha J. Glenn; Thomas M. Habermann; Nancy Lee Harris; Francisco Hernandez-Ilizaliturri; Richard T. Hoppe; Steven M. Horwitz; Mark S. Kaminski; Christopher R. Kelsey; Youn H. Kim; Susan Krivacic; Ann S. LaCasce; Matthew Lunning; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Kenneth Roberts; Ayman A. Saad; Lubomir Sokol; Lode J. Swinnen; Julie M. Vose; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar

doi:10.6004/jnccn.2016.0023

Diffuse large b-cell lymphoma version 1.2016: Clinical practice guidelines in oncology

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan KrivacicAnn S. LaCasce, Matthew Lunning, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar

School of Medicine

Research output: Contribution to journal › Review article › peer-review

55 Scopus citations

Abstract

Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) with varied natural history and response to therapy. In addition, a subset of patients with DLBCL have concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas; DHL) and others have a dual expression of both MYC and BCL2 proteins (double-expressing DLBCL; DEL). The standard of care for the treatment of patients with PMBL, DHL, or DEL has not been established. Adequate immunophenotyping and molecular testing (in selected circumstances) are necessary for the accurate diagnosis of different subtypes of DLBCL. The NCCN Guidelines included in this issue, part of the NCCN Guidelines for non-Hodgkin's lymphomas, address the diagnosis and management of DLBCL and its subtypes.

Original language	English (US)
Pages (from-to)	196-231
Number of pages	36
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	14
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2016.0023
State	Published - Feb 1 2016

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2016.0023

Cite this

Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Byrd, J. C., Fayad, L. E., Fisher, R. I., Glenn, M. J., Habermann, T. M., Harris, N. L., Hernandez-Ilizaliturri, F., Hoppe, R. T., Horwitz, S. M., Kaminski, M. S., Kelsey, C. R., Kim, Y. H., ... Sundar, H. (2016). Diffuse large b-cell lymphoma version 1.2016: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 14(2), 196-231. https://doi.org/10.6004/jnccn.2016.0023

Zelenetz, AD, Gordon, LI, Wierda, WG, Abramson, JS, Advani, RH, Andreadis, CB, Bartlett, N, Byrd, JC, Fayad, LE, Fisher, RI, Glenn, MJ, Habermann, TM, Harris, NL, Hernandez-Ilizaliturri, F, Hoppe, RT, Horwitz, SM, Kaminski, MS, Kelsey, CR, Kim, YH, Krivacic, S, LaCasce, AS, Lunning, M, Nademanee, A, Porcu, P, Press, O, Rabinovitch, R, Reddy, N, Reid, E, Roberts, K, Saad, AA, Sokol, L, Swinnen, LJ, Vose, JM, Yahalom, J, Zafar, N, Dwyer, M & Sundar, H 2016, 'Diffuse large b-cell lymphoma version 1.2016: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 2, pp. 196-231. https://doi.org/10.6004/jnccn.2016.0023

@article{7f9ca987768e4c4e9413e6c8459367d7,

title = "Diffuse large b-cell lymphoma version 1.2016: Clinical practice guidelines in oncology",

abstract = "Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) with varied natural history and response to therapy. In addition, a subset of patients with DLBCL have concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas; DHL) and others have a dual expression of both MYC and BCL2 proteins (double-expressing DLBCL; DEL). The standard of care for the treatment of patients with PMBL, DHL, or DEL has not been established. Adequate immunophenotyping and molecular testing (in selected circumstances) are necessary for the accurate diagnosis of different subtypes of DLBCL. The NCCN Guidelines included in this issue, part of the NCCN Guidelines for non-Hodgkin's lymphomas, address the diagnosis and management of DLBCL and its subtypes.",

author = "Zelenetz, {Andrew D.} and Gordon, {Leo I.} and Wierda, {William G.} and Abramson, {Jeremy S.} and Advani, {Ranjana H.} and Andreadis, {C. Babis} and Nancy Bartlett and Byrd, {John C.} and Fayad, {Luis E.} and Fisher, {Richard I.} and Glenn, {Martha J.} and Habermann, {Thomas M.} and Harris, {Nancy Lee} and Francisco Hernandez-Ilizaliturri and Hoppe, {Richard T.} and Horwitz, {Steven M.} and Kaminski, {Mark S.} and Kelsey, {Christopher R.} and Kim, {Youn H.} and Susan Krivacic and LaCasce, {Ann S.} and Matthew Lunning and Auayporn Nademanee and Pierluigi Porcu and Oliver Press and Rachel Rabinovitch and Nishitha Reddy and Erin Reid and Kenneth Roberts and Saad, {Ayman A.} and Lubomir Sokol and Swinnen, {Lode J.} and Vose, {Julie M.} and Joachim Yahalom and Nadeem Zafar and Mary Dwyer and Hema Sundar",

note = "Publisher Copyright: {\textcopyright} 2016 JNCCN-Journal of the National Comprehensive Cancer Network.",

year = "2016",

month = feb,

day = "1",

doi = "10.6004/jnccn.2016.0023",

language = "English (US)",

volume = "14",

pages = "196--231",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2",

}

TY - JOUR

T1 - Diffuse large b-cell lymphoma version 1.2016

T2 - Clinical practice guidelines in oncology

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Wierda, William G.

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Andreadis, C. Babis

AU - Bartlett, Nancy

AU - Byrd, John C.

AU - Fayad, Luis E.

AU - Fisher, Richard I.

AU - Glenn, Martha J.

AU - Habermann, Thomas M.

AU - Harris, Nancy Lee

AU - Hernandez-Ilizaliturri, Francisco

AU - Hoppe, Richard T.

AU - Horwitz, Steven M.

AU - Kaminski, Mark S.

AU - Kelsey, Christopher R.

AU - Kim, Youn H.

AU - Krivacic, Susan

AU - LaCasce, Ann S.

AU - Lunning, Matthew

AU - Nademanee, Auayporn

AU - Porcu, Pierluigi

AU - Press, Oliver

AU - Rabinovitch, Rachel

AU - Reddy, Nishitha

AU - Reid, Erin

AU - Roberts, Kenneth

AU - Saad, Ayman A.

AU - Sokol, Lubomir

AU - Swinnen, Lode J.

AU - Vose, Julie M.

AU - Yahalom, Joachim

AU - Zafar, Nadeem

AU - Dwyer, Mary

AU - Sundar, Hema

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) with varied natural history and response to therapy. In addition, a subset of patients with DLBCL have concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas; DHL) and others have a dual expression of both MYC and BCL2 proteins (double-expressing DLBCL; DEL). The standard of care for the treatment of patients with PMBL, DHL, or DEL has not been established. Adequate immunophenotyping and molecular testing (in selected circumstances) are necessary for the accurate diagnosis of different subtypes of DLBCL. The NCCN Guidelines included in this issue, part of the NCCN Guidelines for non-Hodgkin's lymphomas, address the diagnosis and management of DLBCL and its subtypes.

AB - Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) with varied natural history and response to therapy. In addition, a subset of patients with DLBCL have concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas; DHL) and others have a dual expression of both MYC and BCL2 proteins (double-expressing DLBCL; DEL). The standard of care for the treatment of patients with PMBL, DHL, or DEL has not been established. Adequate immunophenotyping and molecular testing (in selected circumstances) are necessary for the accurate diagnosis of different subtypes of DLBCL. The NCCN Guidelines included in this issue, part of the NCCN Guidelines for non-Hodgkin's lymphomas, address the diagnosis and management of DLBCL and its subtypes.

UR - http://www.scopus.com/inward/record.url?scp=84957686732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957686732&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2016.0023

DO - 10.6004/jnccn.2016.0023

M3 - Review article

C2 - 26850490

AN - SCOPUS:84957686732

SN - 1540-1405

VL - 14

SP - 196

EP - 231

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Diffuse large b-cell lymphoma version 1.2016: Clinical practice guidelines in oncology

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this